Recent Updates
Recently added Catalysts

Fedratinib

Phase 3FDA approved

Primary Myelofibrosis | Small Molecules | Oncology |Bristol-Myers Squibb Company|Trials Updated: Nov 12, 2026

Fedratinib development status

FDA approval on record Aug 16, 2019 as Inrebic
Approval holderBristol-myers
ApplicationNDA212327
Highest phase Phase 3
Registered trials 11 across 3 sponsors since Nov 2018

Label indication INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) ( 1 ). FDA label

Fedratinib target and mechanism

Molecular targetJAK2, FLT3
Target classInhibitor
ModalitySmall Molecules

Also known as BMS-847943

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials2
Total Enrollment233

FDA Designations

No designations recorded

Fedratinib clinical trials

Fedratinib · 2 trials · 3 indications

Phase 3 1Phase 1/2 1
NCT03952039An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibPrimary Myelofibrosis
COMPLETED202 Analytics
PHASE3COMPLETED
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Primary MyelofibrosisUnlock trial analytics

Study Endpoints

Primary Endpoints

Spleen Volume Response Rate (RR)
From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days

Percentage of participants who have ≥ 35% spleen volume reduction (SVR) at end of cycle 6 A Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment). The RRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in RRs and 95% confidence interval of the difference for fedratinib to BAT.

Maximum Tolerated Dose (MTD)
Up to Cycle 1 (each cycle is 28 days)

is the highest dose that causes DLTs in not more than 33% of the subjects treated with fedratinib in the first cycle with at least 3 evaluable subjects treated at this dose.

Recommended Phase 2 dose (RP2D)
Up to Cycle 1 (each cycle is 28 days)

is a recommended Phase 2 dose that is determined as safe and tolerable by the Safety Review Committee based on the data from the first cycle with at least 3 evaluable subjects treated at each dose of the Phase 1 part.

Response Rate (RR)
Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects who have ≥ 35% SVR at end of Cycle 6 from baseline

Secondary Endpoints

Symptom Response Rate (SRR)
From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days
Spleen Volume Response Rate (RR25)
From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days
Number of Participants With All Grade Treatment Emergent Adverse Events (AEs) and Grade 3 to 4 Treatment Emergent AEs
From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Fedratinib 400mg/dayEXPERIMENTALWill include up to 128 subjects receiving fedratinib 400 mg self-administered Investigational Product (IP) on an outpatient basis, once daily preferably together with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
Best Available Therapy (BAT)ACTIVE_COMPARATORBest-available Investigator-selected therapy included a number of available compounds to treat MF and/or its symptoms and was chosen by the investigator for each subject. Therapy changed at different times during the treatment period. No investigational agents (e.g. not approved for the treatment of any indication) were allowed. BAT also included the choice of no treatment.
Fedratinib AdministrationEXPERIMENTALThe fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.

Interventions

NameTypeDescription
FEDRATINIBDRUGA potent and selective inhibitor of JAK2 kinase activity
Best Available Therapy (BAT)DRUGBest available therapy (BAT)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites107

Inclusion Criteria: 1. Subject is at least 18 years of age at the time of signing the informed consent form (ICF) 2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2 3. Subject has diagnosis of primary myelofibrosis (PMF) according to the 2016 World Healt...

Countries:AustraliaAustriaBelgiumChinaCzechiaFranceGermanyHungaryIrelandItalyNetherlandsPolandRussiaSouth KoreaSpainUnited KingdomJapan
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

HIGHNov 12, 2026NCT04446650Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHNov 12, 2026NCT04446650Status: ACTIVE_NOT_RECRUITING → COMPLETED

Frequently asked questions about Fedratinib

What is fedratinib used for?

Fedratinib is a small-molecule inhibitor studied for primary myelofibrosis, including DIPSS intermediate- or high-risk disease, as well as post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It has been evaluated in patients previously treated with ruxolitinib and in Japanese subjects with these myelofibrosis subtypes.

What does fedratinib target?

Fedratinib targets JAK2 and FLT3, and it is classified as an inhibitor of these kinases. JAK2 is the molecular target named for the compound, with FLT3 also listed as a target. Its development in myelofibrosis centers on this kinase inhibition profile.

Who makes fedratinib?

Fedratinib is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is the sponsor associated with the clinical development program for fedratinib in myelofibrosis.

What phase is fedratinib in?

Fedratinib has reached Phase 3 development in primary myelofibrosis. The Phase 3 study in the program is listed as completed. Fedratinib is an investigational agent in clinical development, and the available program information does not indicate marketing approval.

What clinical trials is fedratinib in?

Fedratinib has been studied in two completed trials. NCT03952039 is a Phase 3 study comparing fedratinib with best available therapy in previously ruxolitinib-treated myelofibrosis patients, enrolling 202 participants across Europe, Asia and Australia. NCT04446650 is a Phase 1/Phase 2 study in Japanese subjects with myelofibrosis, enrolling 31 participants.

How many patients were enrolled in fedratinib trials?

The fedratinib clinical program enrolled 233 participants across its two completed trials. The Phase 3 study NCT03952039 accounted for 202 of these, and the Phase 1/Phase 2 Japanese study NCT04446650 enrolled 31. The Phase 3 trial was randomized and active-controlled.